藥師幫(09885.HK)與越疆科技訂立戰略合作與業務部署協議 推動機器人與醫藥產業融合升級
格隆匯6月3日丨藥師幫(09885.HK)宣佈，於2025年6月3日，集團與越疆科技(2432.HK)訂立戰略合作與業務部署協議，開啓緊密戰略合作，並已展開具體項目的部署。
雙方基於植根行業多年的領先優勢和高度協同的業務生態，決定建立全面戰略合作夥伴關係，將以醫藥協作機器人、醫藥AI大模型、藥品物聯網技術等爲核心，共同探索協作機器人及相關AI產品在藥品研發、倉儲、配送、即時零售、用藥服務等領域的應用，推動機器人與醫藥產業融合升級，努力實現集團「讓好醫好藥普惠可及」和越疆科技「實現人機協作的最優配置」的使命與願景。
在戰略合作初始階段，雙方將率先於藥店、藥倉協作機器人領域展開合作。目前，雙方已確定首個落地項目計劃，已完成可行性論證、技術路線研判、技術方案交換、合適部署環境選定等工作，並已開始搭建測試平臺。
雙方在合作中將遵循協力創新、共贏發展的原則，共享技術資料及合作中新產生的知識產權、商業祕密等。在約定條件下，越疆科技享有獨家生產該項目機器人的權利，而集團則享有在醫藥行業獨家銷售該項目機器人的權利。以此項目爲基礎，依託各自優勢，雙方將在戰略協議框架下不斷開展更多新項目。
集團董事會認爲，與越疆科技建立戰略合作關係，有利於整合資源、協同創新，充分利用雙方行業領先優勢，促進產業科技發展，增進社會健康福祉。
據悉，集團創立於2015年，自成立以來深耕院外醫藥市場與基層醫療領域，致力於賦能醫藥上下遊衆多企業，爲單體藥店和連鎖藥店以及基層醫療機構提供數字化、智能化解決方案。越疆科技亦創立於2015年，憑藉自有全棧協作機器人開發技術，已推出二十餘款協作機器人以滿足醫療健康、汽車、半導體、化工、新零售等衆多場景的使用需求，是協作機器人行業的卓越代表。
據灼識行業諮詢有限公司出具的行業報告顯示，預計2028年全球醫療健康領域的協作機器人市場規模將達373.2百萬美元。集團亦預期機器人市場規模將持續大幅增長，醫藥健康領域將成爲協作機器人應用與推廣的重要場景。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
